Trojan horses and guided missiles: targeted therapies in the war on arthritis

Area of Science:

• Rheumatology
• Drug Delivery Systems
• Nanotechnology

Background:

• Biologic therapies have advanced rheumatoid arthritis (RA) treatment but face challenges with non-response and systemic toxicity.
• Uncontrolled RA leads to joint damage, functional loss, disability, and significant health-economic burden.
• Novel strategies are needed for targeted therapeutic delivery to disease sites to enhance efficacy and minimize systemic side effects.

Purpose of the Study:

• To review recent advancements in polymer conjugation, nanoparticulate drug delivery, and antibody/peptide-based targeting for RA therapeutics.
• To explore strategies for active targeting and in situ drug activity at disease sites.
• To highlight approaches for reducing systemic toxicity in RA treatment.

Main Methods:

• Review of key developments in polymer-drug conjugates over the past five years.
• Analysis of nanotechnology applications in drug encapsulation and delivery for RA.
• Examination of antibody and peptide-based targeting strategies for inflamed synovium.

Main Results:

• Polymer-drug conjugates enhance pharmacokinetics, solubility, and tissue penetration.
• Nanoparticles protect drugs from degradation and reduce systemic toxicity.
• Targeted delivery via antibodies/peptides facilitates selective accumulation in inflamed synovium.

Conclusions:

• Targeted drug delivery systems, including polymer conjugates and nanoparticles, show promise for next-generation RA therapeutics.
• These strategies can improve drug efficacy at disease sites while minimizing off-target effects.
• Combining polymer conjugation, nanotechnology, and targeted moieties offers a platform for more effective and safer RA treatment.